PSMA, His, Human,1mg

Prostate-specific membrane antigen (PSMA) also known as  Folate hydrolase 1 (FOLH1),  Folylpoly-gamma-glutamate carboxypeptidase (FGCP), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1),  is a type II membrane glycoprotein that is expressed in prostate tissue and to a lesser extent in the peripheral and central nervous system, small intestinal, and salivary gland tissues. PSMA has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. The catalytic activity of PSMA involves the release of unsubstituted C-terminal glutamyl residues, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates. PSMA is used as a diagnostic and prognostic indicator of prostate cancer, and as a possible marker for various neurological disorders such as schizophrenia, Alzheimer’s disease, and Huntington’s disease. For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.